Patents Examined by Shanon A. Foley
  • Patent number: 10385319
    Abstract: This application is directed generally to foot-and-mouth disease virus (FMDV) 3C proteases that have been modified by mutating a polynucleotide sequence coding for the FMDV 3C protease. The modified FMDV proteases exhibit proteolytic activity on FMDV P1 precursor protein and exhibit a reduction in one or more toxic or inhibitory properties associated with an unmodified FMDV 3C protease on a host cell used to recombinantly produce it. Vectors carrying polynucleotides encoding modified FMDV 3C protease sequences can induce production of FMDV virus-like particles in a host cell when expressed in the host cell. The modified FMDV 3C proteases can generally be used to produce immunogenic FMDV preparations capable of inducing an immune response against FMDV.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: August 20, 2019
    Assignee: The Governement of the United States of America, as represented by the Secretary of Homeland Security
    Inventors: Michael Puckette, Max V. Rasmussen
  • Patent number: 10383934
    Abstract: The invention provides isolated polynucleotide molecules that comprise a DNA sequence encoding an infectious RNA sequence encoding a genetically-modified North American PRRS virus, methods to make it and related polypeptides, polynucleotides, and various components. Vaccines comprising the genetically modified virus and polynucleotides and a diagnostic kit to distinguish between naturally infected and vaccinated animals are also provided.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: August 20, 2019
    Assignee: Zoetis Services LLC
    Inventors: Jay Gregory Calvert, Robert G. Ankenbauer, Jacqueline Gayle Marx, Douglas S. Pearce, Marcia L. Keith
  • Patent number: 10377798
    Abstract: Compositions and methods useful for producing an immune response in a subject specific for the RSV G protein are described herein. The new methods and compositions described herein are made possible by the development of a new recombinant RSV G protein fragment, which has been engineered for in vitro production and is antigenically similar to the native RSV G protein. The recombinant RSV G protein fragment is capable of inducing the production of RSV G-specific antibodies when injected into a subject. These antibodies can recognize both RSV A and RSV B strains and inhibit infection of both viruses. Accordingly, the compositions and methods described herein may be useful in protecting subjects from RSV infection via immunization, raising antibodies specific for RSV, which can in turn be used to treat RSV infection.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: August 13, 2019
    Assignee: The United States of America, as rerpresented by the Secretary, Department of Health and Human Services
    Inventors: Surender Khurana, Hana Golding
  • Patent number: 10376574
    Abstract: Disclosed herein are compositions and methods useful for immunizing a subject against disease caused by influenza A. Disclosed methods comprise administering to the subject an immunoprotective dose of an immunogenic composition. In certain aspects, the immunogenic composition is a vaccine comprised of a recombinant chimeric hemagglutinin polypeptide. In certain aspects, the subject is a mammal. In further aspects, the mammal is a pig. In still further aspects, the mammal is a human.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: August 13, 2019
    Assignee: South Dakota Board of Regents
    Inventors: Victor Huber, Ying Fang
  • Patent number: 10369213
    Abstract: Methods for improving the drying yield and stability of RSV vaccines comprising a highly thermolabile enveloped live virus and/or one or more RSV protein subunits, are described. Methods for rapid drying of RSV formulations containing between 17.5% and 60% w/w of a non-polymeric sugar and using either conduction or radiation dominant drying mechanisms, are disclosed. The disclosed methods provide for; 1) a dried RSV formulation with improved stability profile; 2) faster drying; and 3) integration of dried RSV into a primary device (such as dual chamber cartridges, foil-pouch devices etc.), pre- as well as post-drying.
    Type: Grant
    Filed: October 13, 2014
    Date of Patent: August 6, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Akhilesh Bhambhani, Robert K. Evans, Lynne A. Isopi
  • Patent number: 10369229
    Abstract: The present invention relates to liposomal vaccine compositions, methods for the manufacture thereof, and methods for the use thereof to stimulate an immune response in an animal. These compositions comprise dimyristoylphosphatidylcholine (“DMPC”); either dimyristoylphosphatidylglycerol (“DMPG”) or dimyristoyltrimethylammonium propane (“DMTAP”) or both DMPC and DMTAP; and at least one sterol derivative providing a covalent anchor for one or more immunogenic polypeptide(s) or carbohydrate(s).
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: August 6, 2019
    Assignees: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, MOLECULAR EXPRESS, INC.
    Inventors: Gary Fujii, Francis C. Szoka, Douglas S. Watson
  • Patent number: 10369212
    Abstract: The invention provides an isolated H3 equine influenza A virus, as well as methods of preparing and using the virus, and genes or proteins thereof.
    Type: Grant
    Filed: June 22, 2018
    Date of Patent: August 6, 2019
    Assignee: Wisconsin Alumni Research Foundation (WARF)
    Inventors: Christopher W. Olsen, Gabriele A. Landolt, Alexander I. Karasin
  • Patent number: 10370416
    Abstract: The present invention includes antigenic fusion proteins, nucleic acids encoding the fusion proteins and methods of making and using the same, wherein the fusion protein comprises three or more different influenza A ectodomains of Matrix Protein 2 (M2e); one or more stem regions of an influenza A hemagglutinin 2 (HA2) protein; and optionally an anthrax antigen, wherein the fusion protein is immunogenic across strains.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: August 6, 2019
    Assignee: Texas Tech University System
    Inventors: Mingtao Zeng, Maria T. Arevalo, Junwei Li
  • Patent number: 10363293
    Abstract: There is described a kit for use in inducing an immune response in a mammal, the kit includes: a first virus that expresses MAGEA3, Human Papilloma Virus E6/E7 fusion protein, human Six-Transmembrane Epithelial Antigen of the Prostate protein, or Cancer Testis Antigen 1, or a variant thereof as an antigenic protein and that is formulated to generate an immunity to the protein or variant thereof in the mammal. The kit also includes a Maraba MG1 virus encoding the same antigen, or a variant of the same antigen. The Maraba MG1 virus is formulated to induce the immune response in the mammal. The first virus is immunologically distinct from the Maraba MG1 virus.
    Type: Grant
    Filed: February 20, 2014
    Date of Patent: July 30, 2019
    Assignee: Turnstone Limited Partnership
    Inventors: David F. Stojdl, John Cameron Bell, Brian Lichty, Jonathan Pol
  • Patent number: 10344293
    Abstract: A recombinant vector for transforming a plant, a plant transformed with the recombinant vector, a plant-made classical swine fever virus antigen pmE2 protein expressed in the plant and uses thereof is provided. By using a recombinant vector having a polynucleotide encoding a GP55 protein of CSFV according to the present invention; and a polynucleotide encoding a cellulose-binding domain protein; and a plant transformed with the recombinant vector, a plant-made classical swine fever virus antigen pmE2 protein may be produced with high efficiency, and has higher safety and stability than those achieved by other production methods. Also, since the plant-derived classical swine fever virus antigen protein pmE2 has a cellulose-binding domain (CBD) protein, it may be usefully used as an effective marker to determine a virus exposure pathway and an antibody producing pathway.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: July 9, 2019
    Assignees: BIO APPLICATIONS INC., REPUBLIC OF KOREA (ANIMAL AND PLANT QUARANTINE AGENCY)
    Inventors: Dong Jun An, Seong In Lim, Jae Young Song, Hye Young Jeoung, Eun Ju Sohn, In Hwan Hwang, Nam Jo Park, Yong Jik Lee, Nam Hyung Kim, Sung Min Gu
  • Patent number: 10335481
    Abstract: It is an object of the present invention to provide a medicament or a pharmaceutical composition, which is effective for the treatment of various cancers. More specifically, the present invention relates to a pharmaceutical composition for use in the treatment of cancers, which comprises rMV-SLAM-blind or rMV-V(?)-SLAM-blind. The pharmaceutical composition has the effect of causing the regression of tumor, even if it is intravenously administered, and it also exhibits effects on cancer metastasized from a primary lesion.
    Type: Grant
    Filed: September 19, 2015
    Date of Patent: July 2, 2019
    Assignee: THE UNIVERSITY OF TOKYO
    Inventors: Chieko Kai, Misako Yoneda
  • Patent number: 10336817
    Abstract: A therapeutic composition of camel milk can include an herbal composition having solid material or liquid extracts from the solid material of at least one of Saussurea acrophila Diels, Saussurea ceratocarpa, and Aucklandia lappa Decne. The solid material may include one or more of parts or the whole of the stem, the bark, the flowers and the roots of one or more, but preferably all of Saussurea acrophila Diels, Saussurea ceratocarpa, and Aucklandia lappa Decne. The therapeutic composition can include camel milk, alone, or in combination with the herbal composition. The camel milk can be HIV-immunized camel milk. The HIV-immunized camel milk can be obtained by immunizing a camel against HIV by administering to the camel the modified DNA plasmids of SEQ. ID No.: 3 and SEQ ID No.: 4 and obtaining the milk from the immunized camel.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: July 2, 2019
    Assignee: Sultan Qaboos University
    Inventors: Sidgi Syed Anwer Abdo Hasson, Ali A. H. Al-Jabri
  • Patent number: 10336988
    Abstract: A method of purification of non-enveloped or pseudo-enveloped virus produced in vitro uses a composition with at least one detergent. A method of purification can use multiple detergents, and a method of determining the presence and/or level of a non-enveloped or pseudo-enveloped virus in a sample includes treating with at least one detergent.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: July 2, 2019
    Assignee: GRIFOLS, S.A.
    Inventors: Brett Buno, Terri Journigan, Joann Hotta, Michael Burdick
  • Patent number: 10335479
    Abstract: The present invention relates to methods for producing dried formulations of biopharmaceutical agents that aim to minimize the loss of activity of the agents upon drying and to provide dried formulations with an extended shelf life. The method comprises the step of drying an aqueous solution comprising, in addition to the biopharmaceutical agent, at least an amino acid, a polyol and a metal salt. Preferably the amino acid is glutamate, the polyol is sorbitol and optionally also mannitol and the metal salt is a magnesium salt. The solution is dried by vacuum drying or by lyophilization. The methods are particularly useful for preparing dried formulations of viruses such as poliovirus or respiratory syncytial virus to be used for vaccination. The invention also relates to dried formulations prepared in accordance with the methods of the invention and to their use as medicaments, e.g. as vaccines.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: July 2, 2019
    Assignee: De Staat der Nederlanden, Vert. Door De Minister Van VWS Ministerie van Volksgezondheid, Welzijn en Sport
    Inventors: Heleen Kraan, Jean-Pierre Amorij, Rimko Ten Have
  • Patent number: 10329342
    Abstract: The invention relates to antibodies, and antigen binding fragments thereof, that neutralize infection of both group A and group B RSV. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized B cells and cultured plasma cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies, antibody fragments, and polypeptides recognized by the antibodies of the invention in screening methods as well as in the diagnosis, treatment and prevention of RSV infection and group A and group B RSV co-infection.
    Type: Grant
    Filed: July 11, 2018
    Date of Patent: June 25, 2019
    Assignee: HUMABS BIOMED SA
    Inventor: Davide Corti
  • Patent number: 10329586
    Abstract: The present invention relates to the field of CAdV vector vaccines, and especially to promoters suitable to express target antigens from such vector vaccines. Disclosed and claimed are recombinant canine adenoviruses, methods of making them, uses for them (including in immunological, immunogenic, vaccine or therapeutic compositions, or, as a vector for cloning, replicating or expressing DNA and methods of using the compositions and vector), expression products from them, and uses for the expression products. Additionally, disclosed and claimed are truncated EHV4 promoters, expression cassettes containing the promoters, and recombinant viruses and plasmids containing the promoters or expression cassettes.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: June 25, 2019
    Assignee: Boehringer Ingelheim Vetmedica GmbH
    Inventors: Andreas Gallei, Ramesh Koukuntla, Robert Barry Mandell, Alice Mundt, Kristina Rehmet, Eric Martin Vaughn
  • Patent number: 10323069
    Abstract: A Senecavirus A polypeptide generally includes at least a portion of 151-434 of SEQ ID NO:1, amino acids 435-673 of SEQ ID NO:1, or amino acids 674-937 of SEQ ID NO:1. The Senecavirus A polypeptide may be used as a capture antigen in a method or device for detecting antibody that specifically binds to the Senecavirus A polypeptide. The Senecavirus A polypeptide may be used as a immunogen to vaccinate a subject having or at risk of having a Senecavirus A infection.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: June 18, 2019
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Michael Murtaugh, Cheryl Dvorak
  • Patent number: 10323289
    Abstract: The present invention relates to a compound inducing activation of HLA-E-restricted CD8 T cells and/or NK cells in a human subject, and reducing HIV viral load, such as glatiramer acetate and glatiramer acetate related active substances and products, for use in the treatment of HIV infection. Macaques chronically infected by SIV have been treated with glatiramer acetate. One of the animals had already progressed to the stage of AIDS. We injected 18 mg of glatiramer acetate three times per week for only 2 weeks. Surprisingly, a strong impact on viral load was observed in response to the treatment. Viremia decreased by 1 log during glatiramer acetate treatment. Even more surprising was the fact that this decrease persisted after stopping the treatment reaching almost a 2 logs decrease in one animal. This is a major result as compared to cART as stopping cART leads to a rebound of the viral load within days.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: June 18, 2019
    Assignee: INSTITUT PASTEUR
    Inventors: Nicolas Huot, Beatrice Jacquelin, Michaela Muller-Trutwin
  • Patent number: 10314905
    Abstract: The invention relates to a genetically modified infectious measles virus derived from a live-attenuated measles virus strain, in which the gene encoding the viral accessory C protein has been knocked out (MV-deltaC). It concerns in particular the use of said genetically modified infectious MV-deltaC in the treatment of malignant tumor or cancer conditions, and for the preparation of agents or compositions for such treatment.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: June 11, 2019
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCENTIFIQUE (CNRS), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT PASTEUR, UNIVERSITE DE NANTES
    Inventors: Frédéric Tangy, Marc Gregoire, Jean-François Fonteneau, Jean-Baptiste Guillerme, Chantal Combredet
  • Patent number: 10316294
    Abstract: This invention provides highly attenuated influenza viruses and vaccines. The attenuated viruses and vaccines proliferate well and have high safety factors. The attenuated viruses providing protective immunity from challenge by virus of the same subtype, as well as cross protection against heterologous viruses.
    Type: Grant
    Filed: March 15, 2014
    Date of Patent: June 11, 2019
    Assignee: The Research Foundation for The State University of New York
    Inventors: Steffen Mueller, Eckard Wimmer, Bruce Futcher, Steven Skiena, Chen Yang